US › Healthcare

Bioatla Inc (BCAB)

US · Healthcare · Biotechnology

$1.47-2.00%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$6.5M

Net profit

$452,000

EPS

$0.14

EPS estimate

$-8.50

Net margin

7.0%

EPS came in at 0.14 against a street estimate of -8.50 — a beat of 101.6%.

Key statistics

Market cap

$2.0M

Forward P/E

0.0

P/B

2.68

Book value

$-21.79

EPS (TTM)

$-24.05

52-week high

$71.50

52-week low

$1.07

50-day MA

$3.20

200-day MA

$11.28

Beta

0.70

Analyst view

Analysts rate Bioatla Inc a buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $10.00.

Shareholding

Insiders

5.41%

Institutions

21.37%

Largest institutional holders

Fund	Stake
Millennium Management LLC	4.24%
Vanguard Capital Management, LLC	1.98%
Acadian Asset Management LLC	1.48%
Geode Capital Management, LLC	0.83%
Deutsche Bank AG	0.63%
Renaissance Technologies Corp	0.61%
BlackRock Inc	0.58%
Citadel Advisors Llc	0.52%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Bioatla Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.